Drug Trial Radar · NCT04590963
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
370
Actual
Start
Oct 2, 2020
Primary completion
May 11, 2022
Study completion Sep 24, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Innate Pharma
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer
Conditions
- Squamous Cell Carcinoma of the Head and Neck
Interventions
MonalizumabDrug
Participants will receive IV infusion of monalizumab as stated in arm description.
CetuximabDrug
Participants will receive IV infusion of cetuximab as stated in arm description.
PlaceboOther
Participants will receive IV infusion of placebo as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis SetTime frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Locations
127 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Chicago, Illinois
Research Site
Westwood, Kansas
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Las Vegas, Nevada
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Columbus, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Camperdown, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Heidelberg, Australia
Research Site
Melbourne, Australia
Research Site
Linz, Austria
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Namur, Belgium
Research Site
Roeselare, Belgium
Research Site
Belo Horizonte, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Panagyurishte, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Victoria, British Columbia, Canada
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.